Bibliographic Details
| Title: |
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects. |
| Authors: |
Brisotto, Giulia1 (AUTHOR) gbrisotto@cro.it, Montico, Marcella2 (AUTHOR) marcella.montico@cro.it, Turetta, Matteo1 (AUTHOR) szanussi@cro.it, Zanussi, Stefania1 (AUTHOR) mrcozzi@cro.it, Cozzi, Maria Rita1 (AUTHOR) rvettori@cro.it, Vettori, Roberto1 (AUTHOR) romina.boschian@cro.it, Boschian Boschin, Romina1 (AUTHOR) asteffan@cro.it, Vinante, Lorenzo3 (AUTHOR) lorenzo.vinante@cro.it, Matrone, Fabio3 (AUTHOR) fabio.matrone@cro.it, Revelant, Alberto3 (AUTHOR) alberto.revelant@cro.it, Palazzari, Elisa3 (AUTHOR) elisa.palazzari@cro.it, Innocente, Roberto3 (AUTHOR) roberto.innocente@cro.it, Fanetti, Giuseppe3 (AUTHOR) giuseppe.fanetti@cro.it, Gerratana, Lorenzo4 (AUTHOR) lorenzo.gerratana@cro.it, Garutti, Mattia4 (AUTHOR) mattia.garutti@cro.it, Lisanti, Camilla4 (AUTHOR) camilla.lisanti@cro.it, Bolzonello, Silvia4 (AUTHOR) silvia.bolzonello@cro.it, Nicoloso, Milena Sabrina5 (AUTHOR) mnicoloso@cro.it, Steffan, Agostino1 (AUTHOR) emuraro@cro.it, Muraro, Elena1 (AUTHOR) |
| Source: |
Viruses (1999-4915). Jun2023, Vol. 15 Issue 6, p1276. 19p. |
| Subject Terms: |
*HUMORAL immunity, *VACCINATION complications, *IMMUNOGLOBULINS, *VACCINE effectiveness, *CELLULAR immunity, *VACCINATION |
| Abstract: |
Cellular and humoral immunity are both required for SARS-CoV-2 infection recovery and vaccine efficacy. The factors affecting mRNA vaccination-induced immune responses, in healthy and fragile subjects, are still under investigation. Thus, we monitored the vaccine-induced cellular and humoral immunity in healthy subjects and cancer patients after vaccination to define whether a different antibody titer reflected similar rates of cellular immune responses and if cancer has an impact on vaccination efficacy. We found that higher titers of antibodies were associated with a higher probability of positive cellular immunity and that this greater immune response was correlated with an increased number of vaccination side effects. Moreover, active T-cell immunity after vaccination was associated with reduced antibody decay. The vaccine-induced cellular immunity appeared more likely in healthy subjects rather than in cancer patients. Lastly, after boosting, we observed a cellular immune conversion in 20% of subjects, and a strong correlation between pre- and post-boosting IFN-γ levels, while antibody levels did not display a similar association. Finally, our data suggested that integrating humoral and cellular immune responses could allow the identification of SARS-CoV-2 vaccine responders and that T-cell responses seem more stable over time compared to antibodies, especially in cancer patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Viruses (1999-4915) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
